Plaque psoriasis: SKYRIZI (risankizumab) is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.1
Psoriatic arthritis: SKYRIZI alone or in combination with methotrexate, for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs.1
Podcast
October: Episode 4 Watch time: 20 min
BAD 2020 virtual congress highlights
The fourth episode focuses on the latest updates and hot topics relating to SKYRIZI (risankizumab) and biologic treatment for moderate to severe psoriasis – presented at the 100th British Association of Dermatologists annual meeting – held virtually this year.
Podcast Series Host
Dr Laura Savage
University of Leeds and Leeds
Teaching Hospitals NHS Trust
Podcast Guest Speakers
Dr Jenny Hughes
The Princess of Wales Hospital, Wales
Dr Hamish Hunter
The University of Manchester
Podcasts:
References
- SKYRIZI (risankizumab) Summary of Product Characteristics.
- Smith CH, et al. BJD 2020, Published: March 18, 2020. DOI:10.1111/bjd.19039.
- BAD 2020 guideline update: NMA bjd19039-sup-0002-FileS2.docx (Accessed August 2020).
UK-RISN-210516 Date of Preparation: October 2021
